Abstract
Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.
Original language | English (US) |
---|---|
Pages (from-to) | 52-55 |
Number of pages | 4 |
Journal | American Journal of Gastroenterology |
Volume | 102 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2007 |
ASJC Scopus subject areas
- Gastroenterology